GlobalMed Telemedicine

Belkins
Founded in early 2002 in Scottsdale, Arizona, GlobalMed is a real-time healthcare delivery system company that deploys state-of-the-art hardware, software, and service solutions that enable leading healthcare professionals to be more effective in providing patient care and more efficient in managing patient information. As the worldwide leader in telemedicine and only vertically-integrated provider, GlobalMed technologies enable more than 3 million telehealth consults annually and are deployed in more than 55 countries around the world. Our evidence-based solutions include telemedicine stations, examination cameras, connected medical devices, video conferencing tools, and software that allow for the dynamic collaboration of healthcare professionals at remote locations across the globe. Partnering with leading medical groups, healthcare enterprises, and government agencies has led to our unparalleled expertise in designing sustainable, integrated connected health programs that deliver best-in-class patient care.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

MCMASTER, SARTORIUS STEDIM BIOTECH TEAM UP TO ADVANCE BIOMANUFACTURING PROCESSES WITH NEXT-GEN TECH

Sartorius Stedim Biotech S.A | August 23, 2021

news image

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has entered into a partnership with McMaster University to improve manufacturing processes of antibody and virus-based treatments for diseases such as COVID-19, cancers, and genetic disorders. Using a state-of-the-art multi-column chromatography system provided by Sartorius Stedim Biotech, the McMaster team will "perfect" a process for the purification of therapeutic viruses that...

Read More

BIO-K PLUS INTERNATIONAL IS EXPANDING ITS PORTFOLIO OF PROBIOTIC PRODUCTS AND IS LAUNCHING A NEW LINE OF FUNCTIONAL BEVERAGES INFUSED WITH PROBIOTICS

Bio-K | October 22, 2020

news image

Bio-K Plus International Inc. (Bio-K Plus), pioneer in the probiotic sector and leader in the biotech industry, is pleased to announce the launch of its new line of functional beverages, Essential. Focused on offering premium quality probiotics that make a real difference in people's lives around the world, the company is adding the Essential line to its existing Pro and Original lines. In keeping with this tradition of high quality, the Essential line fits perfectly into the active and mode...

Read More

INDUSTRIAL IMPACT

BIODURO-SUNDIA ACQUIRES 2ND US-BASED COMMERCIAL DRUG PRODUCT MANUFACTURING FACILITY ALONG WITH COMMERCIAL SUPPLY AGREEMENT

BioDuro-Sundia | November 09, 2021

news image

BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today it has entered into a definitive agreement to acquire a fully-operational 45,000 ft2 commercial oral solid dose drug product manufacturing facility located at 9601 Jeronimo Road, Irvine, CA. As part of the acquisition, BioDuro-Sundia will employ most of the current staff and provide continuous operations to support production of multiple existing products through a comme...

Read More

CARDIFF ONCOLOGY ANNOUNCES $2.5 MILLION EQUITY INVESTMENT BY BIOTECH-FOCUSED FUNDAMENTAL INVESTOR ACORN BIOVENTURES

Cardiff Oncology | May 27, 2020

news image

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and leukemia, today announced it has entered into a definitive securities purchase agreement with biotech-focused fundamental investor, Acorn Bioventures, LP, for $2.5 million.Under the agreement, Acorn Bioventures has agreed to purchas...

Read More
news image

INDUSTRIAL IMPACT

MCMASTER, SARTORIUS STEDIM BIOTECH TEAM UP TO ADVANCE BIOMANUFACTURING PROCESSES WITH NEXT-GEN TECH

Sartorius Stedim Biotech S.A | August 23, 2021

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has entered into a partnership with McMaster University to improve manufacturing processes of antibody and virus-based treatments for diseases such as COVID-19, cancers, and genetic disorders. Using a state-of-the-art multi-column chromatography system provided by Sartorius Stedim Biotech, the McMaster team will "perfect" a process for the purification of therapeutic viruses that...

Read More
news image

BIO-K PLUS INTERNATIONAL IS EXPANDING ITS PORTFOLIO OF PROBIOTIC PRODUCTS AND IS LAUNCHING A NEW LINE OF FUNCTIONAL BEVERAGES INFUSED WITH PROBIOTICS

Bio-K | October 22, 2020

Bio-K Plus International Inc. (Bio-K Plus), pioneer in the probiotic sector and leader in the biotech industry, is pleased to announce the launch of its new line of functional beverages, Essential. Focused on offering premium quality probiotics that make a real difference in people's lives around the world, the company is adding the Essential line to its existing Pro and Original lines. In keeping with this tradition of high quality, the Essential line fits perfectly into the active and mode...

Read More
news image

INDUSTRIAL IMPACT

BIODURO-SUNDIA ACQUIRES 2ND US-BASED COMMERCIAL DRUG PRODUCT MANUFACTURING FACILITY ALONG WITH COMMERCIAL SUPPLY AGREEMENT

BioDuro-Sundia | November 09, 2021

BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today it has entered into a definitive agreement to acquire a fully-operational 45,000 ft2 commercial oral solid dose drug product manufacturing facility located at 9601 Jeronimo Road, Irvine, CA. As part of the acquisition, BioDuro-Sundia will employ most of the current staff and provide continuous operations to support production of multiple existing products through a comme...

Read More
news image

CARDIFF ONCOLOGY ANNOUNCES $2.5 MILLION EQUITY INVESTMENT BY BIOTECH-FOCUSED FUNDAMENTAL INVESTOR ACORN BIOVENTURES

Cardiff Oncology | May 27, 2020

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and leukemia, today announced it has entered into a definitive securities purchase agreement with biotech-focused fundamental investor, Acorn Bioventures, LP, for $2.5 million.Under the agreement, Acorn Bioventures has agreed to purchas...

Read More